|
Post by captsmith77 on Dec 29, 2015 23:51:04 GMT
From their 10-k this morning... Thanks Adam Feuerstein. "On December 22, 2015, the Company received a subpoena from the Securities and Exchange Commission (SEC) which indicates that the agency is conducting a formal investigation. The Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares. The Company is fully cooperating with the SEC in this investigation and is unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it." Adam Feuerstein, Shkrelli, and plenty of others were all in on the well orchestrated short attacks. If you pull up IHUB's top read pages, AVXL is almost always at the top with the traders day after day. I only own a few shares of it, but this "news" doesn't concern me at all, not does it surprise me given the amount of manipulation it's seen.
|
|
|
Post by happyjawa on Dec 30, 2015 4:18:03 GMT
From their 10-k this morning... Thanks Adam Feuerstein. "On December 22, 2015, the Company received a subpoena from the Securities and Exchange Commission (SEC) which indicates that the agency is conducting a formal investigation. The Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares. The Company is fully cooperating with the SEC in this investigation and is unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it." Adam Feuerstein, Shkrelli, and plenty of others were all in on the well orchestrated short attacks. If you pull up IHUB's top read pages, AVXL is almost always at the top with the traders day after day. I only own a few shares of it, but this "news" doesn't concern me at all, not does it surprise me given the amount of manipulation it's seen. I'm not totally up to date on everything that Martin Shkrelli says or does, so I'm not aware of his comments regarding AVXL. With that, my question is do you think he's the primary, or one of the primary reasons for the SEC investigation?
|
|
|
Post by captsmith77 on Dec 30, 2015 4:27:05 GMT
Yes, it's quite possible. He wasn't alone though. Adam Feuerstein had hit pieces ready whenever the company would release news which caused the stock to plummet.
I've seen nothing to hint that the investigation is about the company or it's officers, but rather the manipulation of the stock by short sellers looking to make massive profits with well timed hit pieces against the company through social media and other online outlets. I've read that some stock holders filed complaints with the SEC a while back and heard back that they were looking into the manipulation complaints.
|
|
|
Post by JHam on Dec 30, 2015 6:22:24 GMT
From their 10-k this morning... Thanks Adam Feuerstein. "On December 22, 2015, the Company received a subpoena from the Securities and Exchange Commission (SEC) which indicates that the agency is conducting a formal investigation. The Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares. The Company is fully cooperating with the SEC in this investigation and is unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it." Adam Feuerstein, Shkrelli, and plenty of others were all in on the well orchestrated short attacks.If you pull up IHUB's top read pages, AVXL is almost always at the top with the traders day after day. I only own a few shares of it, but this "news" doesn't concern me at all, not does it surprise me given the amount of manipulation it's seen. What's your evidence for that? I have had pretty much the same sentiment about this stock as they have but never shorted or even thought about touching this thing. Shorting this one at $12 was a no brainier imo, and I would say that the manipulation happened when it was back below $1 getting pumped and promoted. Not when it was getting shorted after that ridiculous data release.
|
|
|
Post by captsmith77 on Dec 30, 2015 9:02:14 GMT
Adam Feuerstein, Shkrelli, and plenty of others were all in on the well orchestrated short attacks.If you pull up IHUB's top read pages, AVXL is almost always at the top with the traders day after day. I only own a few shares of it, but this "news" doesn't concern me at all, not does it surprise me given the amount of manipulation it's seen. What's your evidence for that? I have had pretty much the same sentiment about this stock as they have but never shorted or even thought about touching this thing. Shorting this one at $12 was a no brainier imo, and I would say that the manipulation happened when it was back below $1 getting pumped and promoted. Not when it was getting shorted after that ridiculous data release. That's what I'm hoping the SEC is looking into. Whether it's stock manipulation on the pump side, or on the down side, I believe that it will be either or with their findings. Personally I believe it's because of the numerous complaints after the stock collapsed back in November after positive data release, as the stock initially rose significantly until AF put out his hit piece and other members of his cohorts pounded the stock relentlessly throughout the day and after.
|
|
|
Post by JHam on Dec 30, 2015 9:15:59 GMT
What's your evidence for that? I have had pretty much the same sentiment about this stock as they have but never shorted or even thought about touching this thing. Shorting this one at $12 was a no brainier imo, and I would say that the manipulation happened when it was back below $1 getting pumped and promoted. Not when it was getting shorted after that ridiculous data release. That's what I'm hoping the SEC is looking into. Whether it's stock manipulation on the pump side, or on the down side, I believe that it will be either or with their findings. Personally I believe it's because of the numerous complaints after the stock collapsed back in November after positive data release, as the stock initially rose significantly until AF put out his hit piece and other members of his cohorts pounded the stock relentlessly throughout the day and after. AF was going after this company before they even released data though. He was not the only one to write a "hit piece". There was no way the stock wasn't going to come crashing down after that kind of data release and especially after that kind of unjustified runup. All in my opinion.
|
|
|
Post by JHam on Dec 30, 2015 9:24:36 GMT
|
|
|
Post by JHam on Dec 30, 2015 17:23:31 GMT
Bloomberg gets it. Can't wait to see the trolls go after this author now too. www.bloomberg.com/gadfly/articles/2015-12-30/anavex-subpoena-news-overshadows-the-biotech-firm-s-bigger-issuesThis paragraph perfectly sums up the problem most have with this company and why it was shorted to hell: Of course, approval of any kind is highly uncertain. No disease provokes as much hype and as much disappointment as Alzheimer's. There hasn't been a significant new drug in a decade, and there's reason to be skeptical of Anavex's chances. The company's shares actually fell after a press release where it announced that Anavex 2-73 on its own had succeeded in a phase 2(a) study. That would ordinarily be good news, but it turns out the trial was tiny (32 patients), extremely short (5 weeks), had a small effect and wasn't conducted in a double-blind fashion, making the results almost impossible to interpret, as they just as easily could have been a placebo effect.
|
|
|
Post by iamaverb on Sept 28, 2016 14:25:07 GMT
Anavex has been on the move lately on news on the Parkinson disease and now the MLS front. I have held this for it's work in Alzheimer's a few years and have just now broken even.
10:19 AM EDT, 09/28/2016 (MT Newswires) -- Anavex Life Sciences(AVXL) , a clinical stage biopharmaceutical company that develops drugs for treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's and multiple sclerosis, said it signed an agreement under which Biogen (BIIB) will test its leading drug candidate.
The company said Biogen will test its Anavex 2-73 drug that's designed to battle demyelinating diseases such as multiple sclerosis, which requires understanding of why remyelination fails. The studies will examine the therapeutic role Anavex 2-73 may play in permitting remyelination.
Anavex 273 is currently in a Phase 2a clinical trial for Alzheimer's disease after completing Phase 1 trials with a clean safety profile. Pre-clinical studies showed the drug can halt or reverse the course of Alzheimer's. The Michael J. Fox Foundation for Parkinson's Research awarded Anavex a research grant to develop the drug for for the treatment of Parkinson's disease, the company said.
Up $1.27 / 41%
|
|